Human Exendin-4 ELISA Kit (DEIABL227)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
Human serum or plasma
Species Reactivity
N/A
Intended Use
For the quantitative determination of Exendin-4 in human serum or plasma using competitive ELISA method.
Contents of Kit
1.ELISA buffer concentrate (50ml 20x concentrate)
2.96-well immunoplate with plate sealer
3.Antiserum (lyophilized powder)
4.Standard (1mg lyophilized powder)
5.Biotinylated tracer (lyophilized powder)
6.Streptavidin-HRP (100μl 200x concentrate)
7.TMB substrate stock solution (1.5ml)
8.TMB substrate buffer (15ml citrate buffer)
9.Stop solution 2 N HCl (15 ml)
10.Standard diluent 8 ml (peptide-free human serum)
11.Datasheet
12.Protocols
Storage
After you receive the kit, store the lyophilized components and standard diluent at -20°C for up to one year from the kit's assembly date. The remaining components should be stored in the refrigerator (4 - 8°C) also up to 1 year. Long term storage, improper storage conditions and large temperature fluctuation cycles may cause precipitates in the TMB solution and in the ELISA buffer concentrate. These precipitates should not affect the assay noticeably. Nevertheless, if you observe such precipitates, we recommend to avoid them by allowing them to sink to the bottom.
Detection Range
0-25ng/ml
General Description
Exendin-4 is a 39 amino acid peptide amide known to be a long-acting agonist of the glucagon-like peptide 1 receptor (GLP-1). It is involved in glucose-dependent enhancement of insulin secretion, reduction of hyperglycemia, and glucosedependent suppression of high glucagon secretion.
This ELISA was developed with serum from rabbits immunized with Exendin-4 coupled to a carrier protein.
Standard Curve

Citations


Have you cited DEIABL227 in a publication? Let us know and earn a reward for your research.

Related Products


Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Repurpose of exendin-4 for the treatment of preterm neonatal brain injury

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Authors: Ferreira, E. Rocha; Jonsdotter, A.; Jinnai, M.; Poupon, L.; Leverin, A. L.; Carlsson, Y.; Rahim, A. A.; Hagberg, H.

Inhibitory effects of peripheral administration of exendin-4 on food intake are attenuated by lesions of the central nucleus of amygdala

BRAIN RESEARCH BULLETIN

Authors: Qiao, Hu; Ren, Wan-ni; Li, Hai-zhen; Hou, Yu-xia

The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 suppresses food intake and decreases body weight. However, the mediating site(s) of action of the anorectic effects induced by peripheral administration of GLP-1R agonists are not well known. The present study investigated the effects of bilateral lesions of the central nucleus of the amygdala (CeA) on the suppression of chow and high-sucrose food intake by exendin-4 in rats. Adult male Sprague-Dawley rats with bilateral sham or electrolytic lesions (400 mu A; 25 s) of the CeA were used for this experiment. No significant difference was found in the daily chow intake and high-sucrose food intake in rats with CeA lesion compared to sham-operated rats. Bilateral lesions of the CeA significantly attenuated the suppression of high-sucrose food intake by i.p. exendin-4, but not the suppression of chow intake. These results suggest that a mediating role of the CeA on the peripheral effects of exendin-4.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket